UMB Bank’s Niagen Bioscience NAGE Stock Holding History

UMB Bank’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-693	Closed	-$1.06K	–	1754
2023 Q1	$1.06K	Buy	+693	New	+$1.23K	﹤0.01%	1595

Other funds holding NAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UMB Bank's NAGE Position: Q2 2023 in Review

UMB Bank sold out of Niagen Bioscience (NAGE) in Q2 2023, closing a stake of 693 shares — an estimated $1.06K sold.

UMB Bank first reported a position in NAGE in Q1 2023 and held it in 1 quarter. The position peaked at $1.06K in Q1 2023. 55 funds tracked by Wall St. Rank hold NAGE as of Q2 2023.

UMB Bank reported no remaining Niagen Bioscience position as of Q2 2023 after selling out during the quarter.
UMB Bank sold 693 Niagen Bioscience shares in Q2 2023, an estimated $1.06K.
UMB Bank first reported a position in Niagen Bioscience in Q1 2023 and held it in 1 quarter.
UMB Bank's Niagen Bioscience position peaked at $1.06K in Q1 2023.
55 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2023.

Based on UMB Bank's 13F filing for Q2 2023, filed 25 Jul 2023.